

Original Research Article

SOME HAEMATOLOGICAL PARAMETERS AND FREE RADICALS STATUS OF

DIABETIC PATIENTS IN SOKOTO, NIGERIA

ABSTRACT

Background: World Health Organization statistics identify 150 million people with diabetes mellitus worldwide and suggest that this figure may double by 2025.

Aim: This research was conducted to determine the status of some haematological parameters and free radicals among diabetic patients attending Specialist Hospital, Sokoto.

Study Design: This was a case control study involving two groups; 29 controls (non-diabetic) and 58 diabetic subjects.

Methodology: The participants were divided into two groups; 29 controls (non-diabetic) and 58 diabetic subjects. 5ml of blood was collected into EDTA and plain containers for haematological and free radicals' analysis respectively. The FBC investigation was carried out using automated haematology analyser while MDA and GPx investigations were carried out using chemical method and enzymatic respectively. The FBC, GPx and MDA status of both control and subjects were compared in this study.

Duration: The study lasted for a period of six months between April to September, 2017

Results: The results obtained in this study showed a significant increase in WBC, neutrophil, eosinophil and Platelet count parameters of diabetic subjects ($P \leq 0.05$) when compared with controls, while other FBC parameters and free radicals (MDA and GPx) were not significant ($P > 0.05$).

Conclusion: This research shows that WBC count, neutrophil, eosinophil and platelet count of the diabetic patients increased. There is need for a further research on direct free radical estimation and total antioxidant status in relation to diabetes, which gives more information than the indirect method of estimation. It is recommended that white blood cells and platelet levels should be closely monitored for proper management diabetic patients.

Key words: **Haematological, Parameters, Free Radicals, Diabetic, Patients, Sokoto**

1. INTRODUCTION

Diabetes mellitus (DM) is a complex metabolic disorder involving many organs and can devastate the lives of affected individuals (1). It is characterized with chronic high blood glucose

that could lead to morbidity and mortality (2). The number of people suffering from diabetes worldwide is increasing at an alarming rate. It is predicted that about 366 million people are likely to be diabetic by the year 2030 (3).

However, diabetes is mostly classified basically into two major types: Type I Diabetes (T1D) and Type II Diabetes (T2D). Type I diabetes (Insulin dependent) which is due to immune mediated beta-cells destruction, leading to insulin deficiency, while Type II diabetes (Non-insulin dependent) that occur as a result of insulin secretory defect and insulin resistance. About 5-10% of the total cases of diabetes worldwide are due to T1D. T1D is the most common type of diabetes in children and adolescents while Type II Diabetes (T2D) is common among young adults (4,5). At least 90% of adult individuals with diabetes have type II diabetes (6).

Diabetes is the most common cause of chronic kidney disease (CKD) in the Western World, present in nearly two thirds of all patients with renal impairment (7). Anemia is a common complication of CKD, affecting over half of all patients (7, 8). Consequently, diabetes is also the most common cause of renal anemia. However, over-and-above diabetes as simply a cause of renal disease, anemia is also more common in patients with diabetes than those with renal disease of other causes. For example, the Third National Health and Nutrition Examination Survey (NHANES-III), found people in the general population with diabetes were nearly twice as likely to have anaemia, when compared to people without diabetes, but with a similar degree of renal impairment (9). Anaemia also develops earlier in patients with diabetes than in patients with renal impairment from other causes (10).

Full blood count (FBC) is a common blood test to check a person's general health or to screen for conditions such as anaemia. A full blood count measures the status of a number of different features of the blood, including the amount of haemoglobin in the blood, the number of red blood

cells (red cell count), the percentage of blood cells as a proportion of the total blood volume (haematocrit or packed cell volume), the volume of red blood cells (mean cell volume), the average amount of haemoglobin in the red blood cells (known as mean cell haemoglobin), the number of white blood cells (white cell count), the percentages of the different types of white blood cells (leucocyte differential count), and the number of platelets (11).

Mansi and Lahham revealed that various haematological parameters including packed cell volume (PCV), haemoglobin (Hb), red blood cells (RBC) and white blood cells (WBC) were reported to be altered during the course of diabetes mellitus (12). Patients with diabetes mellitus show a significant derangement in various haematological parameters (3). Anaemia is a common finding in patients with diabetes, particularly in those with overt nephropathy or renal impairment (14). Anaemia has also been shown to be a risk factor for cardiovascular disease in diabetic patients particularly those with chronic kidney disorder. About 27% of diabetics' patients are anemic (15).

So many studies were carried out by different scholars in order to show the prevalence of anaemia in diabetes mellitus. Colak reported that diabetes mellitus causes the development of hypochronic anaemia due to a fall in the iron content of the body resulting from oxidative stress associated with the condition (16). A previous study also showed that the mean values of total red blood cells (TRBC), haemoglobin (Hb), packed cell volume (PCV) and mean cell haemoglobin concentration (MCHC) for the diabetic patients were found to be lower than the values of control group, indicating the presence of anemia in the former group (17). Similarly a previous report indicated that the occurrence of anemia in diabetes mellitus is due to the increased non-enzymatic glycosylation of RBC membrane proteins, which correlates with hyperglycaemia (14,18). In red blood cell production, erythropoietin (EPO) is produced by the

kidneys. Kidney damage at several levels is a complication of diabetes and one problem often leads to the other. Changes in the kidneys that occur with diabetes range from diabetic nephropathy all the way to chronic kidney disease. Early detection and treatment is essential to prevent or delay disease progression (19).

Chung and colleague, showed that the white blood cells (WBC) might play a role in the development and progression of diabetic complications (20). Studies also shows that peripheral white blood cell (WBC) count might be associated with type II diabetes coronary artery disease (CAD), stroke, micro and macro vascular complications (21,22). Increased differential cell counts, including counts of eosinophils, neutrophils, and monocytes, also indicate the future incidence of coronary artery disease (CAD) (23,24,25).

Reactive oxygen species (ROS) is a collective term used for a group of oxidants, which are either free radicals or molecular species capable of generating free radicals. Free radicals may be defined as any chemical species that contains unpaired electrons. Unpaired electrons increase the chemical reactivity of an atom or a molecule. The most important oxygen-containing free radicals in many disease states are hydroxyl radical, superoxide anion radical, hydrogen peroxide, oxygen singlet, hypochlorite, nitric oxide radical, and peroxynitrite radical (26).

Antioxidants can be defined as substances that are able, at relatively low concentrations, to compete with other oxidizable substrates, and thus, to significantly delay or inhibit the oxidation of these substrates. This definition includes the enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase, as well as nonenzymatic compounds such as tocopherol (vitamin E), β -carotene, ascorbic acid (vitamin C), and glutathione, which scavenge the reactive oxygen species (27). Oxidative stress is due to a disturbance in the balance between

the production of ROS and the efficiency of the antioxidant defense. In other words, oxidative stress results if excessive production of ROS overwhelms the antioxidant defence (28).

Under normal metabolic conditions, these ROS are eliminated rapidly in normal cells by the antioxidant defense system. However, several studies have shown that high levels of free radicals and the simultaneously declined antioxidant enzyme levels lead to cell damage, inactivation of enzymes, and lipid peroxidation. Accumulated evidence indicates that oxidative stress-activated signaling pathways mediate insulin resistance and β -cell dysfunction. These consequences of oxidative stress can promote the development of diabetes complications. Therefore, oxidative stress, antioxidant defense, cellular redox status should be regarded as the central players in diabetes and its complications (29). Another study also shown that persistent hyperglycaemia in Diabetes mellitus is usually accompanied by increased production of free radicals especially Reactive Oxygen Species (ROS) or impaired antioxidant defenses. Weak defence system of the body becomes unable to counteract the enhanced ROS generation and as a result condition of imbalance between ROS and their protection occurs which leads to domination of the condition of oxidative stress (30,31). This oxidative stress is known to play a pivotal role in cellular injury from hyperglycemia (32).

Diabetes mellitus and one of its complications, diabetic nephropathy, represent a leading cause of end-stage renal diseases (ESRD) in the developed countries especially United States and Europe (33,34). Hyperglycaemia of diabetes mellitus and its attendant metabolic syndromes that is insulin resistance, hyperglycaemia, hypertension, dyslipidaemia, obesity, and some social characters of these patients e.g. smoking and the use of xenobiotics, predispose to diabetic nephropathy. These accelerate free radical generation and attenuate the antioxidant defense system creating oxidative stress (35,36,37). Consequently, increased free radical production and

attenuation of antioxidant system is currently receiving the highest attention when discussing diabetic nephropathy (38). The aim of this study is to determine the status of some haematological parameters (full blood count) and some free radicals status (malondialdehyde and glutathione) among diabetic patients attending Specialist Hospital, Sokoto. There is paucity of data on haematological parameters and free radical status of diabetic patients in Sokoto, North Western Nigeria. Data generated in this study will help policy makers and management of Specialist Hospital Sokoto on steps to take for effective diagnosis and management of diabetes and associated complications in patients.

2. METHODOLOGY

2.1 Study Area

This study was conducted in the Specialist Hospital, Sokoto. Samples were analyzed in the Haematology and Chemical pathology laboratory departments of Usmanu Danfodiyo University Teaching Hospital (UDUTH). The Specialist Hospital is a secondary health care institution located in Sokoto Metropolis, committed to the provision of quality healthcare services to people in Sokoto State and its surrounding. Sokoto state is located in the northwest of Nigeria, near to the confluence of the Sokoto River and the Rima River. It's located between longitudes 11° 30' to 13° 50' East and latitude 4° to 6° North. It has a land area of about 25,973sq kilometers and a density of 170 sq kilometer. The state is in the dry Sahel surrounded by sandy terrain and isolated hills with an average annual temperature of 28.3°C (82.9°F). Sokoto state had a population of 3.6 million as at the 2006 census with projected population of 5,117,511.236 in 2017. The Metropolis is estimated to have a population of 427,760 people, majority of which are

Hausa and Fulani while Zabarmawa, Tuareg and other non- indigenous settlers from the neighboring areas form the minority of the population (39).

2.2 Study Population

The study population for this research include 58 patients with diabetes as subjects and 29 non-diabetic patients who were monitored as controls. Both subject and controls were recruited from the Specialist Hospital, Sokoto, North-Western Nigeria.

2.3 Study Design

This case control study which involves collection of blood samples from diabetic patients and non-diabetic patients and tested for full blood count, Malondialdehyde (MDA) and glutathione estimation.

2.4 Sample Size Determination

The sample size was determined according to Cochran, (40) using the formula:

n = minimum sample size
z = standard normal deviation and probability.
P = prevalence or proportion of value to be estimated from previous studies.
q = Proportion of failure (= 1 - P)
d = precision, tolerance limit, the minimum is 0.05. Using prevalence of 3.9% (41)

$$\text{Therefore } n = \frac{Z^2 pq}{d^2}$$

Where Z = 95% (1.96)
P = 3.9% (0.039)
q = 1 - 0.039 = 0.961
d = 5% (0.05)

$$\text{Therefore, } n = \frac{(1.96)^2 (0.039) (0.961)}{0.05^2}$$

$$n = 58$$

2.5 Ethical Consideration

Ethical approval of this study was obtained from the ethical committee of Specialist Hospital, Sokoto.

2.6 Inclusion and Exclusion Criteria

Inclusion criteria

- Confirmed patients with diabetes of all age group attending Specialist Hospital, Sokoto.
- Diabetic patients who were willing to give a written informed consent.

Exclusion criteria

- Non-diabetic patients.
- Diabetic patients who refused to give a written informed consent.
- Diabetic patients not attending Specialist Hospital, Sokoto.

2.7 Informed Consent

Written informed consent was obtained from the patients or guardian of all study participants.

2.8 Collection and Method of Analysis

5.0 millilitres of blood was collected from each participant. 2.0 millilitres was transformed into EDTA bottle and the remaining 3.0 millilitres into a plain container. The EDTA anticoagulated sample was used for full blood count estimation while sample from the plain tubes was allowed to clot to obtain the serum for glutathione and malondialdehyde estimation. These samples were tested in Haematology and Chemical pathology Laboratory departments of Usmanu Danfodiyo University Teaching Hospital (UDUTH).

Full Blood Count was carried out using the five-part automated haematology analyser (Mythic 22CT, 2008). Glutathione Peroxidase Activity was assayed using Cayman's Glutathione Peroxidase Assay Kit (42) and Serum Malondialdehyde was determined using chemical method (43)

2.9 Data Analysis

Data obtained was entered into a statistical package (such as SPSS version 22) on a computer to define the nature of the distribution of data for each group. Statistical differences of data was analyzed using series of statistical analysis such as mean, standard deviation, t-test, ANOVA was used to compare the mean $\pm$ SD of the full blood count and free radicals of diabetic patients and the normal control subjects depending on the nature and distribution of data. Probability (i.e $P \leq 0.05$) was used to determine the level of significant for all statistical analysis.

3.0 RESULT

A total of 58 diabetic patients and 29 non-diabetic (controls) were recruited for the study. The diabetics comprised of 37 (63.79%) males and 21(36.21%) females with overall mean age of 49.21 ± 11.37 and were tested for FBC, MDA and GPx.

Table 1. shows the FBC and free radicals (MDA and GPx) status among diabetic subjects and controls. There was a statistical difference in WBC, Neutrophil, Eosinophil and Platelet count parameters between the diabetic subjects and controls ($P \leq 0.05$). There was no statistical difference in GPx, MDA and other FBC parameters between the diabetic subjects and controls ($P > 0.05$).

Table 1: FBC and free radicals (MDA and GPx) parameters in study groups

Parameters	Control (29)	Diabetic Subjects (58)	t-value	p-value
WBCC ($\times 10^9/l$)	5.28 $\pm$ 1.51	6.67 $\pm$ 1.89	3.47	0.01
RBCC ($\times 10^6/\mu l$)	4.26 $\pm$ 0.77	4.12 $\pm$ 0.60	0.42	0.08
Haemoglobin (g/dl)	12.47 $\pm$ 2.15	11.81 $\pm$ 1.74	-1.53	0.13
PCV ($\times 10^9/l$)	35.75 $\pm$ 6.37	34.00 $\pm$ 4.77	-1.43	0.16
Monocyte ($\times 10^9/l$)	8.04 $\pm$ 5.14	5.90 $\pm$ 3.75	-2.22	0.29

Neutrophil ($\times 10^9/l$)	44.80 $\pm$ 10.34	50.44 $\pm$ 9.19	2.60	0.01
Lymphocyte ($\times 10^9/l$)	44.67 $\pm$ 8.86	43.46 $\pm$ 8.36	-0.62	0.54
Eosinophil ($\times 10^9/l$)	0.41 $\pm$ 0.16	1.79 $\pm$ 0.50	-1.95	0.05
Basophil ($\times 10^9/l$)	0.41 $\pm$ 0.16	0.49 $\pm$ 0.24	1.62	0.11
Platelet ($\times 10^9/l$)	263.90 $\pm$ 71.00	297.53 $\pm$ 79.14	-3.34	0.02
GPx (nmol/mn/ml)	14.15 $\pm$ 12.00	10.90 $\pm$ 7.51	-1.51	0.14
MDA (μ mol/l)	25.22 $\pm$ 8.63	28.72 $\pm$ 11.17	1.48	0.14

Table 1 above shows the FBC and free radicals (MDA and GPx) status among diabetic subjects and controls. There was a statistical difference in WBC, Neutrophil, Eosinophil and Platelet count parameters between the diabetic subjects and controls ($P \leq 0.05$). There was no statistical difference in GPx, MDA and other FBC parameters between the diabetic subjects and controls ($P > 0.05$).

KEY:

PCV- Pack cell volume, MDA- Malondialdehyde, GPx- Glutathione peroxidase, RBCC- Red blood cell count, WBCC- White blood cell count, μ Mol/l- Micromole per litre, nmol/mn/ml- Number of mole per minute per milliliter.

4. DISCUSSION

In this present study, we observed that the RBC, Hb and also PCV value as an index of anaemia were lower among diabetic subjects compared to non-diabetic controls, though they were not statistically significant. This research is at variance with the previous findings which says that anaemia is prevalent among diabetic's patients and may also be significant in determining the outcome of heart failure and hypoxia-induced organ damage in patients with diabetes(44).

Oyedemi and colleagues also found that anaemia is a common finding in patients with diabetes, particularly in those with overt nephropathy or renal impairment (14). Anaemia is associated with an increased risk of diabetic complications including nephropathy, retinopathy and macrovascular disease. Similarly, a previous study observed that the mean values of TRBC, Hb, PCV and MCHC for the diabetic patients are lower than the values of control group, indicating the presence of anemia in the former group (17). The observed decrease in the RBC, Hb and PCV values of the diabetic patients could be attributed as a result of poor dieting and low standard of living by the diabetic patients.

The result also showed that the WBC, neutrophil, eosinophil and PLT counts were significantly higher among diabetic subjects compared to non-diabetics. However, a positive correlation was observed between raised TWBC, PLT and diabetes. In this present study, we observed that WBC count, neutrophil, eosinophil and PLT counts were significantly higher among diabetic subjects compared to non-diabetics ($P \leq 0.05$). Our finding is in agreement with previous reports which suggest that platelet counts are higher and contribute to vascular events in patients with insulin resistance (45). Diabetes mellitus is a metabolic syndrome. Previous report shows that PLT and TWBC counts are higher in patients with T1D than without the metabolic syndrome and that the rise is in a “dose-dependent” fashion. Increase in PLT and TWBC with increasing blood glucose in patients with T1D could be a result of a stress response. WBC counts correlated positively with platelet counts, which may suggest that a shared mechanism drives both the elevated platelet and WBC counts in patients with this syndrome (46). Clinically elevated platelet counts are frequently seen in diabetics with a long duration of disease. Elevated platelet levels as well as platelet dysfunction could be injurious to the microcirculation and enhance the risk for vascular complications. Previous report seems to suggest the possibility that elevated

platelet count could be used as a prognostic indicator of future diabetic complications (47). Similarly, previous report has shown that raised PLT values are commonly seen in inflammatory and infectious diseases. Reactive thrombocytosis has also been reported among diabetic patients particularly those with poor diabetic control associated with raised blood sugar level (48). However, the observed increase in WBC, neutrophil, eosinophil and PLT counts could be attributed as a result of poor health status of the diabetic patients in the locality, thereby exposing them to bacteria and parasitic infections.

There was a decrease in GPx levels among diabetic patients in comparison with the controls according to our study, though not statistically significant ($P= 0.14$). This decrease among diabetic subjects could be attributed to increased oxidative stress as evidenced by lipid peroxidation. The antioxidant decrease reflects the war of antioxidants against oxidative stress to minimize the oxidative damage. When the total antioxidant status is high and enough to combat the oxidative stress the MDA levels are in the normal limits and vice versa. However, our finding is in variance with a study from South Karnataka on individual antioxidants among diabetics that reported a significant decrease of erythrocyte reduced Glutathione (GSH) whereas oxidized Glutathione (GST) levels are slightly elevated among the diabetics. Similar study from Hungary also reports both increase of few and decrease of other few individual antioxidant enzymes (49). A recent study also reported decreased Total Antioxidant Status in comparison to Diabetic patients with neuropathy by using the Cayman kit (50). Duman and colleagues, from Turkey have observed significant decrease of antioxidants among the diabetic population (51). Several studies have revealed lowered antioxidant and enhanced peroxidative status in diabetes condition (52). There is still a need for further research in the field of free radicals and antioxidants. The

prime aim should be in elucidating the underlying mechanisms by which free radicals bring about the pathogenesis. This would help expand the scope of treatment options.

5. CONCLUSION

In this research we found that, some haematological parameters such as WBC count, neutrophil, eosinophil and platelet counts were higher in diabetic subjects, while other FBC parameters, MDA and GPx were not affected. Basophil was also affected based on marital status. MDA is affected based on age group, while other socio-demographic factors have no effect on the FBC, MDA and GPx parameters of the diabetic patients and controls.

6. RECOMMENDATIONS

There is need for a further research on direct free radical estimation and total antioxidant status in relation to diabetes, which gives more information than the indirect method of estimation. It is recommended that white blood cells and platelet levels should be closely monitored when treating diabetic patients. It is recommended that, FBC and free radical status of the diabetic patients should be made a routine test for proper management of diabetes.

CONSENT

As per international standard or university standard, patient's written informed consent was obtained before participating in the study.

ETHICAL APPROVAL

Ethical approval was obtained from Ethics committee of Specialist Hospital, Sokoto, Nigeria.

REFERENCES

1. Khuwaja, A.K., Khowaja, L.A., Cosgrove, P. (2010). The economic costs of diabetes in developing countries:some concerns and recommendations. *Diabetologia*; **53**:389-90.

2. Mohammed, A., Tanko, Y., Okasha, M.A., Magaji, R.A., Yaro, A.H. (2007). Effects of Saqueous leaves extract of *Ocimum gratissimum* on blood glucose levels of streptozotocininduced diabetic Wistar rats. *African Journal of Biotechnology*; **6**:2087-90.
3. Wild, S., Roglic, G., Green, A., Sicree, R., King, H. (2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care*; **27**(5): 1047–53.
4. Ayepola, O.R., Brooks, N.L., Oguntibeju, O.O. (2014). Oxidative Stress and Diabetic Complications: The Role of Antioxidant Vitamins and Flavonoids. Retrieved from <https://www.intechopen.com/books/antioxidant-antidiabetic-agents-and-human-health/oxidative-stress-and-diabetic-complications-the-role-of-antioxidant-vitamins-and-flavonoids>.
5. Butterfiel, D.A., Tanuja, K., Howard, B., Subramaniam, R., Hall, N., Hensley, K., Yatin, S., Allen, K., Micheal, A., Aksenova, M., John, C. (1998). Structural and functional changes in proteins induced by free radical-mediated oxidative stress and protective action of the antioxidants N-tert-butyl-alpha-phenylnitron and vitamin E. *Annals of the New York Academy of Science*; **854**:448–462.
6. Robert, F. Jr., Melissa C. S. (2016) Diabetes (Mellitus, Type 1 and Type 2). (Updated 3 march 2016) Available at: <http://www.emedicinehealth.com/script/main/mobileart-emh.asp?articlekey=177731>.
7. McClellan, W., Aronoff, S.L., Bolton, W.K., Hood, S., Lorber, D.L., Tang, K. L., Tse, T.F., Wasserman, B., Leiserowitz, M. (2004). The prevalence of anaemia in patients with chronic kidney disease. *Current Medical Research and Opinion*; **20**:1501-10.

8. United State Renal Data System (USRDS). (2002). Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2001. *erfiel* 1998.
9. Astor, B. C., Muntner, P., Levin, A., Eristace, J. A., Coresh, J. (2002). Association of kidney function with anemia: the third national health and nutrition examination survey (1988–1994). *Archives of Internal Medicine*; **162**:1401–1408.
10. Dikow, R., Schwenger, V., Schomig, M. (2001). How should we manage anaemia in patients with diabetes? *Nephrology Dialysis and Transplant*; **17**:67-72.
11. Rob, H. (2016). What is a normal full blood count? (Updated 14 september2016) Available at: <http://www.m.webmd.boots.com/a-to-z-guides/full-blood-count>.
12. Mansi, K., Lahham, J. (2008). Effects of *Artemisia sieberi* Besser (a. herba-alba) on heart rate and some hematological values in normal and alloxan-induced diabetic rats. *Experimental and Clinical Sciences International online Journal for advances in Sciences*; **12**:647-657.
13. Al –Khoury, S., Afzali, B., Shah, N., Covic, A., Thomas, S., Goldsmith, D. J. (2006). Predictors Anaemia in diabetic patients with chronic kidney disease prevalence and predictors. *Diabetologia*; **49**:1183-1189.
14. Oyedemi, S.O., Yakubu, M.T., Afolayan, A. J. (2011). Antidiabetic activities of aqueous leaves ex- tract of *Leonotis leonurus* in streptozotocin induced diabetic rats. *Journal of Medicinal Plant Research*; **5**: 119-125.
15. Colak, S., GeyiKoghu, F., Aslana, A., Deniz, G.Y. (2012). Effects of Lichen extracts on haematological parameters of rats with experimental insulin-dependent diabetes mellitus. *Toxicology and Industrial Health publishers*.

15. Dipta, T.F., Quamrun, N., Subhagata, C. (2009). Pattern of Haematological Disorders in a Tertiary Diabetic Hospital: A Pilot Study. *Journal of Bangladesh College of Physicians and Surgeons*; **27**:148-154.
17. Ruchi K., Pradeep B. (2012). A comparative study of haematological parameters in type i diabetes mellitus patients & healthy young adolescents. *International Journal of Biological and Medical Research*; **3**:2429-2432.
18. Thomas, S., Rampersad, M. (2004). Anaemia in diabetes. *Acta Diabetologica*; **1**:13-17.
19. Uko, E.K., Erhabor, O., Isaac, I.Z., Abdulrahaman, Y., Adias, T.C., Sani, Y.I., Shehu, R.S., Liman, H.M., Dalltu, M.K., and Mainasara, A.S. (2013). Some Haematological Parameters in Patients with Type-1 Diabetes in Sokoto, North Western Nigeria. *Journal of Blood Lymph*; **3**:1
20. Chung, F.M., Jack C.R.T., Dao-Ming C., Shyi-Jang S., Yau-Jiunn L., (2005). Peripheral Total and Differential Leukocyte Count in Diabetic Nephropathy. *Diabetes Care*; **28**:1710–1717.
21. Ohshita, K., Yamane, K., Hanafusa, M., Mori, H., Mito, K., Okubo, M., Hara, H., Kohno, N. (2004). Elevated white blood cell count in subjects with impaired glucose tolerance. *Diabetes Care*; **27**:491– 496.
22. Ford, E.S., (2002). Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. *American Journal of Epidemiology*; **155**:57– 64.
23. Madjid, M., Awan, I., Willerson, J.T., Casscells, S.W. (2004). Leukocyte count and coronary heart disease: implications for risk assessment. *Journal of the American College of Cardiology*; **44**: 1945–1956.

24. Olivares, R., Ducimetiere, P., Claude, J.R. (1993). Monocyte count: a risk factor for coronary heart disease. *American Journal of Epidemiology*; **137**:49–53.
25. Prentice, R.L., Szatrowski, T.P., Fujikura, T., Kato, H., Mason, M.W., Hamilton, H.H. (1982). Leukocyte counts and coronary heart disease in a Japanese cohort. *American Journal of Epidemiology*; **116**:496–509.
26. Young, I.S., Woodside, J.V. (2001). Antioxidants in health and disease. *Journal of Clinical Pathology*; **54**:176–86.
27. Tirzitis, G., Bartosz, G. (2010). Determination of antiradical and antioxidant activity: basic principles and new insights. *Acta Biochimica Polonica Journal*; **57**:139–42.
28. Kang, D.H. (2002). Oxidative Stress, DNA Damage, and Breast Cancer. *Advanced Critical Care*; **13**:540-549.
29. Xiao, L., (2003). Oxidative stress and diabetes. *Free radicals in biology and medicine*; **77**:222.
30. Rosen, P., Wiernsperger, N.F. (2006). Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. *Diabetes/Metabolism Research Reviews*; **22**:323–30.
31. Ceriello, A. (2005). Postprandial hyperglycemia and diabetes complications: Is it time to treat? *Diabetes*; **54**:1–7.
32. Asmah, R.H., Yeboah, G., Asare-Anane, H., Antwi-Baffour, S., Archampong, T.N., Brown, C.A., Amegatcher, G., Adjei, D.N., Dzudzor, B., Akpalu, J., Ayeh-Kumi, P.F. (2015). Relationship between oxidative stress and haematological indices in patients with diabetes in the Ghanaian population. *Clinical Diabetes and Endocrinology*; **1**:7

33. Goligorsky, M.S., Chen, J., Brodsky, S. (2000). Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. *Hypertension*; **37**:744-748.
34. Nuhad, I., Bryan, B., Piotr, S., Eberhard, R. (1999). Perspective in renal medicine: renal disease and hypertension in non-insulin dependent diabetes mellitus. *Kidney International*; **55**:1-28.
35. McCord, J.M. (2000). The evolution of free radicals and oxidative stress. *American Journal of Medicine*; **108**:652-659.
36. Richard, O, C, III. (1998). Role of Nitric oxide in cardiovascular disease: focus on the endothelium. *Clinical Chemistry*; **44**:1809-1819.
37. Gutteride, J.M.C., Halliwell. (1994). Antioxidants in nutrition, health and disease. *Oxford University Press, Oxford*; 90-123.
38. Mshelia, D.S. (2004). Role of free radicals in pathogenesis of diabetes nephropathy. *Annals of African Medicine*; **2**:55-62.
39. National Population Commission (NPC). (2007). National Census Figures, Abuja, Nigeria.
40. Cochran, W.G. (1977). Sampling techniques (3rd edition). New York: *John Wiley and Sons*.
41. International Diabetes Federation (IDF). (2013). Diabetes Atlas, Sixth Edition: p56.
42. Paglia, D. E., Valentine, W. N. J. (1967). Technical bulletin. *Journal of Laboratory and Clinical Medicine*; **70**: 158-169.
43. Shah, J.K., Walker, A.M. (1989). Quantitative determination of MDA. *Biochemica et Biophysica Acta*; **11**:207-11.
44. Thomas, M. C., MacIssaac, R. J. (2005). Anemia in diabetes; an emerging complication of microvascular disease. *Current Diabetes Review*; **1**: 107- 126.

45. Taniguchi, A., Fukushima, M., Seino, Y., Sakai, M., Yoshii, S. (2003). Platelet count is independently associated with insulin resistance in non-obese Japanese type 2 diabetic patients. *Metabolism*; **52**: 1246-1249.
46. Jesri, A., Okonofua, E. C., Egan, B. M. (2005). Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. *Journal of Clinical Hypertension*; **7**: 705-711.
47. Sterner, G., Carlson, J., Ekberg, G. (1998). Raised platelet levels in diabetes mellitus complicated with nephropathy. *Journal Internal Medicine*; **244**: 437-441.
48. A., Antonioli, E., Guglielmelli, P., Vannucchi, A. M., Delaini, F. (2008). Leukocytosis and risk stratification assessment in essential thrombocythemia. *Journal of Clinical Oncology*; **26**: 2732-2736.
49. Szaleczky, E., Prechl, J., Fehér, J., Anikó, S. (1999). Alterations in enzymatic antioxidant defence in diabetes mellitus - a rational approach. *Postgraduate Medical Journals*; **75**: **13**–7.
50. Hamood, I. and Al Neaimy, K. S. A. (2008). Antioxidants in type 2 Diabetic neuropathy. *Bahrain Medical Bulletin*; **30**(**1**):1–7.
51. Duman, B. S., Oeztuerk, M., Yilmazer, S., Hatemi, H. (2003). Malondialdehyde and Total antioxidant status in the Turkish Patients with Type 2 Diabetes Mellitus. *Tohoku Journal of Experimental Medicine*; **201**(**3**):147–55.
52. Kalaivanam, K. N., Dharmalingam, M., Marcus, S. R. (2006). Lipid peroxidation in Type 2 diabetes mellitus. *International Journal of Diabetes in Developing Countries*; **26**:30–2.